FINANCIAL INFORMATION BY BUSINESS AREA
Quarterly data
Net sales by business area
| 2024 | 2025 | 2026 | |||||||||
| SEKm | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | ||
| Labtech | 863 | 941 | 852 | 1,141 | 989 | 985 | 906 | 1,073 | 985 | ||
| Medtech | 1,708 | 1,615 | 1,494 | 1,679 | 1,714 | 1,594 | 1,524 | 1,663 | 1,661 | ||
| Group items | -1 | -2 | -2 | -2 | -1 | -1 | -1 | -3 | -1 | ||
| The Group | 2,570 | 2,554 | 2,344 | 2,818 | 2,702 | 2,578 | 2,429 | 2,733 | 2,645 | ||
EBITA by business area
| 2024 | 2025 | 2026 | |||||||||
| SEKm | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | ||
| Labtech | 99 | 109 | 76 | 161 | 120 | 122 | 102 | 152 | 129 | ||
| Medtech | 198 | 200 | 153 | 195 | 231 | 198 | 177 | 357 | 212 | ||
| Group items | -6 | -10 | -6 | -10 | -8 | -13 | -9 | -12 | -9 | ||
| EBITA | 291 | 299 | 223 | 346 | 343 | 307 | 270 | 497 | 332 | ||
| | |||||||||||
| 2024 | 2025 | 2026 | |||||||||
| % | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | ||
| Labtech | 11.5 | 11.6 | 8.9 | 14.1 | 12.1 | 12.4 | 11.2 | 14.1 | 13.1 | ||
| Medtech | 11.6 | 12.3 | 10.3 | 11.6 | 13.5 | 12.4 | 11.6 | 21.5 | 12.8 | ||
| The Group’s EBITA margin | 11.3 | 11.7 | 9.5 | 12.3 | 12.7 | 11.9 | 11.1 | 18.2 | 12.5 | ||
Adjusted EBITA / Adjusted EBITA margin by business area
| 2024 | 2025 | 2026 | |||||||||
| SEKm | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | ||
| Labtech | 99 | 109 | 76 | 161 | 120 | 122 | 102 | 152 | 129 | ||
| Medtech | 204 | 193 | 160 | 195 | 231 | 198 | 177 | 199 | 212 | ||
| Group items | -6 | -10 | -6 | -10 | -8 | -13 | -9 | -12 | -9 | ||
| Adjusted EBITA | 297 | 292 | 230 | 346 | 343 | 307 | 270 | 339 | 332 | ||
| | |||||||||||
| 2024 | 2025 | 2026 | |||||||||
| % | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | ||
| Labtech | 11.5 | 11.6 | 8.9 | 14.1 | 12.1 | 12.4 | 11.2 | 14.1 | 13.1 | ||
| Medtech | 11.9 | 11.9 | 10.7 | 11.6 | 13.5 | 12.4 | 11.6 | 12.0 | 12.8 | ||
| The Group’s adjusted EBITA margin | 11.6 | 11.4 | 9.8 | 12.3 | 12.7 | 11.9 | 11.1 | 12.4 | 12.5 | ||